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Abstract
Background: In Southeast Asia, dengue viruses often co-circulate with other flaviviruses such as
Japanese encephalitis virus, and due to the presence of shared antigenic epitopes it is often difficult
to use serological methods to distinguish between previous infections by these flaviviruses.
Results: Convalescent sera from 69 individuals who were known to have had dengue or Japanese
encephalitis virus infection were tested by western blotting against dengue, Japanese encephalitis
and West Nile virus antigens. We determined that individuals who had been infected with dengue
viruses had IgG responses against the premembrane protein of dengue viruses but not Japanese
encephalitis, whereas individuals who had been infected with Japanese encephalitis had IgG specific
for the premembrane protein of Japanese encephalitis virus but not the dengue viruses. None
reacted with the premembrane protein of West Nile virus. Using the Pearson Chi Square test, it
was determined that the difference between the two groups was highly significant with a p value of
<0.001.
Conclusion: The use of flavivirus premembrane protein in seroepidemiological studies will be
useful in determining what flaviviruses have circulated in a community.
Background
Dengue haemorrhagic fever (DHF) was first described in
Southeast Asia half a century ago, and has became increas-
ingly important as a cause of paediatric morbidity and
mortality in Southeast Asia over these past decades. Al-
though the dengue viruses have circulated in this and oth-
er parts of the world previously, the viruses caused dengue
fever (DF) rather than the more severe DHF, which has
been for the most part, a Southeast Asian phenomenon
since the 1950s. In recent years however, epidemics of
dengue outside Southeast Asia have been associated with
DHF and it has become a disease of global importance.
Dengue viruses are not the only flaviviruses which have
spread beyond their traditional ecologies. This is evident
from the establishment and maintenance of West Nile vi-
rus (WNV) in the eastern United States over the last 3
summers. Japanese encephalitis virus (JEV) is another ex-
ample of a flavivirus extending its boundaries. First isolat-
ed in Japan in 1935, JEV had been causing extensive
outbreaks of encephalitis in parts of East Asia until the in-
troduction of a vaccine in the middle of the last century.
Although Japanese encephalitis has now been controlled
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problem in countries west and south of Japan, and more
recently has spread as far as northern Australia. Under
these circumstances, it is not unusual to find that more
than one flavivirus co-circulates in an area. In Southeast
Asia, the most important of these are the dengue viruses
and JEV. In South America it is likely that the dengue vi-
ruses may co-circulate with yellow fever virus (YFV) while
it is becoming likely that in parts of eastern North America
we should be concerned about co-circulating St Louis en-
cephalitis (SLE) virus and WNV [1,2].
All these flaviviruses share antigenic epitopes, which elicit
antibodies commonly referred to as cross-reacting anti-
bodies. These flavivirus cross-reactive responses can con-
found the interpretation of serological tests, and it is often
impossible to determine with certainty the infecting virus
without resorting to performing neutralization tests. This
characteristic was most clearly noticed in the days when
serological confirmation of dengue and JEV infection was
based on the demonstration of a four-fold seroconversion
of antibody titre by the haemagglutination inhibition test.
It was standard practice to test two fold serial dilutions of
paired sera from each patient against haemagglutinins
prepared from all 4 dengue serotypes as well as JEV to de-
termine recent infection retrospectively. While IgM cap-
ture ELISAs using antigens prepared from different
flaviviruses may today be used with care to determine re-
cent infection, ELISA methods to differentiate between
IgG responses to different flaviviruses are not as straight-
forward.
Although the determination of the presence of specific
IgG may no longer be useful for the diagnosis of acute in-
fection, seroepidemiological studies are best carried out
using ELISAs to detect specific IgG. There is today an ex-
panded effort to develop vaccines against various flavivi-
ruses, including DENV, JEV and WNV. There is thus clearly
a need for an ELISA based test for the determination of fla-
vivirus infection history during field site preparation
when these vaccine candidates are taken to phase III trials.
During the course of our routine service for the serodiag-
nosis of recent dengue infection we noticed that in immu-
noblot analysis of serum from dengue patients, IgG was
able to recognize the envelope as well as the NS1 proteins
of DENV as well as JEV. However, antibodies against
DENV prM, were not reactive with JEV prM. In this study
we present data to show that antibodies against prM of
DENV and JEV can reliably identify which flavivirus or fla-
viviruses an individual has previously been infected with.
We believe that this specificity of antibodies against prM
may be useful in the development of simple methods for
determining the flavivirus infection history of an individ-
ual as well as for seroepidemiological studies of flavivirus
infections in situations where more than one flavivirus co-
circulates.
Results and Discussion
Western blots probed with dengue or JEV positive sera
Two equivalent SDS PAGE gels were transferred to nitro-
cellulose membranes and the resulting blots were probed
with two serum pools: a high titred positive reference den-
gue sera (HPR) and JEV positive sera from swine (PPJ).
HPR had been pooled from more than 50 specimens ob-
tained in the Malaysian states of Penang and Perak be-
tween 1989 and 1994. The swine sera had been pooled
from more than 50 specimens collected during a period of
JEV activity in Penang in 1989. Figure 1 (A) shows that the
envelope and NS1 proteins of the dengue viruses and JEV
were strongly reactive with HPR. NS1 is seen here in its
dimeric form because the samples were not heated and
were run under non-reducing conditions. What is remark-
able however, is that the prM band of each of the 4 dengue
serotypes was recognized by HPR while the prM band of
JEV was not picked up at all. In the complementary blot in
Figure 1 (B), PPJ can be seen to have reacted strongly with
the envelope proteins of all the dengue virus serotypes in
addition to the envelope protein of JEV. There was some
weak cross reactivity with the dengue virus NS1 dimer but
PPJ did not recognize any of the prM bands in the lanes
containing dengue virus serotypes. Since dengue viruses
do not infect swine, PPJ can be confidently considered to
be homotypic JEV serum and this specificity for JEV prM
was explored further by probing western blot strips with
individual IgG positive swine sera.
A group (JS) of 31 JEV positive sera from swine in a highly
JEV endemic area were tested separately on strips contain-
ing JEV antigens and DENV3 antigens. DENV3 was select-
ed to represent the 4 dengue virus serotypes because it was
the most prevalent serotype circulating in the human pop-
ulation during the period of collection of the swine speci-
mens. To our surprise, only 29 of the 31 sera were positive
for JEV prM, although these had been scored strongly pos-
itive in a dot enzyme immunoassay using JEV antigens.
However, none of the 31 sera recognized the prM of
DENV3, although the envelope band was reactive in these
strips. It is intriguing that in this sample, 2 (6.5%) of the
strongly positive swine sera recognized JEV and WNV en-
velope protein but not prM. It is possible that these sera
were from animals with more recent infection and had
not yet had raised antibodies to prM. Alternatively, there
might be another flavivirus circulating locally which can
infect swine.
Next we tested a group (JH) of convalescent sera from 16
children who had had JEV infection proven by IgM cap-
ture ELISA (MAC ELISA) using JEV and DENV3 western
blot strips. Here again, DENV3 was chosen because it wasPage 2 of 6
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time these patients presented. These sera had previously
been shown to have seroconverted with respect to IgG
against JEV antigens, and in the western blot analysis all
these convalescent sera were reactive with JEV prM but not
DENV prM, confirming our observations with the swine
sera that antibodies elicited against JEV prM do not cross
react with DENV prM.
Since there are 4 different serotypes of dengue viruses, and
in Southeast Asia, these viruses are commonly co-endemic
with JEV, it is not possible to be certain that a patient with
a proven dengue infection did not previously have a JEV
infection, thus effectively having a secondary flavivirus
immune response. In Malaysia this is entirely possible be-
cause dengue can occur in older patients in contrast with
JEV which is mainly a paediatric disease. We addressed
this problem by testing 2 different groups of patients with
dengue proven by MAC ELISA. In the first group (DP) of
sera collected in Penang where the prevalence of JEV is
low, there were 10 convalescent sera and all were found to
be reactive with prM of at least one dengue virus serotype,
but only 1 was also reactive with the prM of JEV. The sec-
ond group (DS) of sera was collected in Sarawak where
the prevalence of JEV is very high. Of the 12 convalescent
sera tested, 11 were reactive with prM of at least one den-
gue virus serotype and 5 were reactive with the prM of JEV.
Interestingly, the single specimen which was not reactive
with dengue prM was reactive with prM of JEV raising the
possibility that this patient had had a JEV infection in the
past, and a recent dengue infection which had not yet elic-
ited antibodies against dengue prM. Indeed this patient
had neutralizing antibodies against both dengue viruses
as well as JEV at titres of 1:640 and 1:160 respectively.
The data from the individual serum groups are summa-
rized in Table 1. The JS and JH groups were combined to
form a JEV positive subgroup and the DP and DS groups
were combined to form a dengue positive subgroup.
There were a total of 69 specimens tested and the Pear-
son's chi-square test was applied, showing a significant
difference between the two groups with a p value of
<0.001 (JMP Start Statistics, SAS Institute, Inc., USA). In
this study, it was not possible to determine if antibody re-
sponses to the prM protein of each DENV serotype was as-
sociated with prior infection with that particular serotype.
This is because there is currently no convincing method to
determine infecting dengue serotype retrospectively since
even DENV neutralizing antibodies can be cross reactive.
JEV specific sera do not recognize WNV prM
JEV and WNV belong to the same flavivirus antigenic
group, and with the heightened interest in WNV in the
United States, we decided to determine if JEV specific sera
would discriminate between JEV and WNV prM. We tested
the same 16 human JEV positive sera from group JH on
western blot strips prepared from WNV lysates. None of
the JEV positive sera reacted with WNV prM although
there was substantial cross reactivity with WNV envelope
protein. Some representative western blot strips are
shown in Figure 2.
Conclusions
Antibodies against the prM protein of JEV do not react
with the prM of dengue viruses or WNV. Conversely anti-
bodies against the prM protein of dengue viruses do not
react with JEV prM. It is conceivable that prM is a useful
viral protein to investigate as a tool in differentiating anti-
body responses to different flaviviruses and thus provide
a method to investigate specific flavivirus seroepidemiol-
ogy in a community.
Figure 1
Immunoblots Probed With High Titred Antiserum
Pools. SDS PAGE was run with samples which were not
reduced with 2-mercaptoethanol and not heated before elec-
trotransfer to nitrocellulose membranes. Immunoblots were
probed with (A): convalescent dengue serum (HPR) and (B):
JEV positive swine serum (PPJ). Lane C contains uninfected
cell lysates while Lanes 1, 2, 3, 4 and 5 contain lysates of
DENV1, 2, 3, 4 and JEV respectively. The position for bands
of NS1 dimer, E and prM are labeled on the right.Page 3 of 6
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Source of virus and monoclonal antibodies
Four prototype dengue virus serotypes, Japanese encepha-
litis virus, Nakayama strain and West Nile Virus, Egypt
101 strain, were all adapted to culture in the C6/36 Aedes
albopictus cell line. All the flaviviruses used in this study
were passaged from suckling mouse brain preparations
obtained originally from the collection of Dr James S Por-
terfield while he was at Oxford University. The mouse
monoclonal antibodies, MF4/5/A5/C3-3/D4/C6 (dengue
group reactive) and MV12/1/C2-2/1 (JEV specific), were
provided by Venture Technologies, Penang, Malaysia.
Preparation of virus antigens
C6/36 cells were grown in 75 mm3 tissue culture flasks
(Nunc, Denmark) in Leibovitz 15 medium containing 5%
heat inactivated foetal bovine serum and antibiotics (Pen-
icillin, 50 U/ml and streptomycin sulphate 50 mg/ml). Vi-
rus stocks were inoculated onto confluent monolayers
after removal of growth medium and allowed to adsorb to
the cells by rocking the flasks at room temperature for one
hour, after which the flasks were replenished with 20 ml
of maintenance medium (Leibovitz 15 medium with 3%
heat inactivated bovine serum and antibiotics), then incu-
bated stationary in an incubator set at 30°C. Maintenance
medium was changed after 2 to 4 days (depending on the
virus) and the culture supernatants and infected cells were
harvested when cytopathic effect was apparent through-
out the monolayer. The culture supernatants were clari-
fied by centrifugation for 10 minutes at 1000 rpm at 4°C
in a Beckman Avanti J-25 with a JS7.5 rotor, and stored in
aliquots at -80°C until use. The infected monolayers were
washed with phosphate buffered saline (PBS) and lysed in
2 ml of a hypotonic buffer containing 1% TX-100. Intact
nuclei were removed by brief centrifugation at 14,000
rpm in a microcentrifuge (Eppendorf, 5415C) and the
lysate supernatants (referred to as "lysates") were aliquot-
ed and stored at -80°C until use. Culture supernatants
were used for two purposes: as infectious virus in plaque
assays as well as virus antigen source in the IgM or mouse
immunoglobulin capture ELISAs. When used as antigens
in an IgM capture assay, the culture supernatants of
DENV1, 2, 3 and 4 were pooled in a ratio which was de-
signed to ensure equal antigen titres for all serotypes. The
lysates were used for the immunoblots as well as for coat-
ing 96 well plates for indirect ELISAs. Control antigens
were prepared in an identical manner using mock infected
cells harvested at the same time as the oldest virus cul-
tures.
Serum specimens
Three pools of sera were used as controls: High Positive
Reference (HPR) contained pooled convalescent serum
from patients with dengue. Negative Reference Serum
(NRS) was serum pooled from individual healthy donors
who were negative for dengue and JEV IgG when tested in
a dot enzyme immunoassay at 1:250 dilution. Pooled
Positive JEV (PPJ) serum was pooled from swine slaugh-
tered in the Penang state abbatoir in 1989 after a JEV out-
break in the state. The sera had been tested by
haemagglutination inhibition test and dot enzyme immu-
noassay for antibodies to JEV [3].
Four groups of individual serum were used in this study
and are described here as follows:
Group JS: JEV IgG positive serum from 31 individual do-
mestic swine from JEV endemic areas, as determined by
dot enzyme immunoassay.
Group JH: Convalescent sera from 16 individuals with en-
cephalitis due to JEV as determined by IgM capture ELISA.
Table 1: prM Reactivity of Different Serum Groups






JS JEV positive swine 31 0 (0) 29 (93.5)
JH Convalescent JE, human 16 0(0) 16 (100)
ALL JEV SUBTOTAL OF JEV SERA 47 0 45 (95.7%)
DP Convalescent dengue, 
Penang (low incidence JE)
10 10 (100) 1 (10)
DS Convalescent dengue, 
Sarawak
(high incidence JE)
12 11 (91.7) 5(41.7)
ALL DENV SUBTOTAL OF
DENV SERA
22 21 (95.5%) 6 (27.3%)Page 4 of 6
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10 patients with dengue fever or dengue haemorrhagic fe-
ver where recent dengue was determined by IgM capture
ELISA. Patients were from Penang in West Malaysia where
the incidence of Japanese encephalitis is low.
Group DS: Convalescent dengue IgG positive sera from 12
patients with dengue fever or dengue haemorrhagic fever
where recent dengue was determined by IgM capture ELI-
SA. Patients were from Sarawak in Malaysian Borneo,
where the incidence of Japanese encephalitis is high.
IgM Capture ELISA (MAC ELISA) to distinguish recent den-
gue and JEV infection
When Innis and coworkers described the IgM capture ELI-
SA for dengue in 1989, they included JEV antigens to dif-
ferentiate dengue and JEV infections [4]. This detail is
important in settings where both dengue and JEV co-circu-
late and we have adapted this basic assay to utilize culture
supernatants instead of mouse brain derived antigens and
monoclonal instead of polyclonal antibodies. We validat-
ed the use of culture supernatants as the antigen source
previously [5] and the current assay uses in addition an
equal mixture of the monoclonal antibodies MF4/5/A5/
C3-3/D4/C6 and MV12/1/C2-2/1, which together can rec-
ognize all 4 dengue serotypes as well as JEV. Table 2 shows
adjusted OD readings of a mouse immunoglobulin cap-
ture ELISA (MIC ELISA) to show the specificities of these
2 monoclonal antibodies. Thus MF4/5/A5/C3-3/D4/C6 is
a dengue group reactive antibody and MV12/1/C2-2/1 is
JEV specific.
Briefly, 96 well flat bottom plates (Maxisorb, Nunc, Den-
mark) were coated overnight at 4°C with rabbit anti-hu-
man µ chain (Dako A425) at 1:2000 dilution in
carbonate-bicarbonate buffer pH 9.6 before blocking with
PBS containing 1% casein. Washed plates were loaded
with patients serum (in triplicate) at 1:100 dilution in PBS
containing 1% casein and incubated at room temperature
for 2 hours before washing with PBS containing 0.5%
Tween 20 (PBS-Tween). Each specimen was then tested
against 3 different antigens: DENV pool (of all 4 sero-
types), JEV and the uninfected cell control. These antigens
were loaded into the wells for an overnight incubation at
4°C and then washed with PBS-Tween prior to the antigen
detection step, which uses a mixture of the monoclonal
antibodies MF4/5/A5/C3-3/D4/C6 and MV12/1/C2-2/1
for one hour at room temperature. After washing with
PBS-Tween the bound monoclonals were detected using
an anti-mouse immunoglobulin conjugated with HRP
(Dako P260) at 1:2000 dilution for one hour at room
temperature. Colour development was achieved after
washing using the substrate, o-phenylenediamine – hy-
drogen peroxide for 30 minutes at room temperature. The
reaction was stopped with sulphuric acid and the optical
density (OD) was read at 490 nm wavelength using 650
nm as the reference.
Interpretation of MAC ELISA readings
Every individual serum specimen included an internal cell
control antigen. The OD reading of the well containing
the cell control antigen was subtracted from each of the
wells containing the virus antigens (DENV in one and JEV
in the other) to give an adjusted OD which took account
of any reaction the patient might have had against mos-
quito antigens. Each plate also contained 3 sets of positive
and negative serum controls. A specimen was considered
to be IgM positive when the ratio:
adjusted OD of virus / mean adjusted OD negative control
>= 5.
It is often the case that patients will have IgM which react
with both DENV and JEV. This should be expected since
flaviviruses have shared epitopes, and in our experience it
is not difficult to determine which is the most likely in-
fecting virus by comparing the adjusted OD of DENV with
that of JEV. Normally this would be much higher for one
than the other, and would clearly indicate the recent in-
fecting virus. It is thus critically important when using
MAC ELISAs to run DENV and JEV antigens in parallel as
first described by Innis and coworkers[4] in order to avoid
misdiagnosis in countries where both viruses co-circulate.
In this current assay we have not attempted to define units
as described by Innis and coworkers since to be useful,
this would require standard reagents made freely available
to all, a resource not yet in existence. In a few instances
Figure 2
Representative Immunoblot Strips Probed With
Individual Sera. Strips contain viral antigens separated by
SDS PAGE under non-reducing conditions without heating:
(1) DENV3, (2) JEV, (3) WNV, (4) uninfected cell control.
Each set of strips were probed with a single convalescent
serum specimen (1:1000, overnight) from an individual with a
JEV infection (A – D) while the set labeled E was probed with
HPR.Page 5 of 6
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both DENV and JEV and in such cases it would be difficult
to determine with confidence whether the recent infecting
virus was a DENV, JEV or some other flavivirus. A spread-
sheet (see Additional File) is provided to demonstrate
what OD readings are seen in a clinical situation where
both dengue and JE viruses circulate in the same location.
Mouse Immunoglobulin Capture ELISA (MIC ELISA) to 
identify monoclonal antibody specificity
Essentially this was similar to the MAC ELISA with the fol-
lowing differences: The plates were coated with rabbit
anti-mouse immunoglobulin (Dako Z412) at 1:2000 di-
lution in order to capture mouse immunoglobulins from
undiluted hybridoma culture supernatants overnight at
4°C. The bound mouse antibodies were incubated with
various cell culture derived antigens as described above,
and the antigens bound were detected using high titred
human anti-dengue IgG (HPR) followed by anti-human γ
conjugated to HRP (Dako P214) at 1:5000 dilution.
Western blotting
Lysates from infected and uninfected cells were run on
12% discontinuous SDS polyacrylamide gels and elec-
troblotted onto nitrocellulose membranes. The mem-
branes were then blocked with PBS containing 5% non-fat
skimmed milk (PBS-SM) for 30 minutes. Membranes
were then washed and probed with serum diluted 1:1000
in PBS-SM with 10 mM sodium azide by incubating over-
night on a rocker at room temperature. The following
morning the membranes were washed extensively with
PBS (5 washes consisting of a 20 minutes soak with rock-
ing) and then incubated with the relevant HRP conjugate
for 4 hours with rocking. For human serum, we used anti-
human IgG HRP (Dako P214) and for swine serum we
used Protein A-HRP (KPL 14-50-00). Reactive bands were
visualized by incubating with 4-chloro-1-naphthol and
hydrogen peroxide for 30 minutes. The reaction was
stopped with water.
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In order to illustrate the kind of OD readings which can be expected in a 
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representative data of IgM capture ELISA readings for real life examples 
of patients from dengue and JEV endemic areas.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2180-2-9-S1.xls]Page 6 of 6
(page number not for citation purposes)
